Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CirRNA-seq of the fourth passage xenografts treated with 5-Fu and PBS

ABSTRACT: cirRNA-seq of the fourth passage xenografts treated with 5-Fu and PBS

PROVIDER: PRJNA608689 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11178348_1.fastq.gz	Fastqsanger.gz
	SRR11178348_2.fastq.gz	Fastqsanger.gz
	SRR11178349_1.fastq.gz	Fastqsanger.gz
	SRR11178349_2.fastq.gz	Fastqsanger.gz
	SRR11178350_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

cirRNA-seq of the fourth passage xenografts treated with 5-Fu and PBS

Project description:In this study, we established a successive xenograft model to enrich Epstein-Barr virus-associated gastric carcinoma (EBVaGC) cancer stem cells (CSCs) through long-term treatment of EBVaGC cell line SNU719 with 5-Fluorouraci (5-Fu) in mice vivo passage. Simply, NOD/SCID mice injected in the subcutaneous with SNU719 were treated with 5-Fu weekly until xenografts reached 1.5 cm diameter and the mice were euthanizedand single-cell suspensions were obtainedby collagenasedigestion. Then the purified cells were passaged in 5-Fu-treated NOD/SCID mice as above. After four successive generations,we obtained theSNU-4th cells from the fourth passage xenografts treated with 5-Fu. Compared with parental SNU719 cells, SNU-4th cells possessed the stemness characters. Increasing evidence have proved that circular RNA (circRNA) play an important role in maintaining the tumor phenotype. So, we compared circRNAs expression between the fourth passage xenografts treated with 5-Fu and PBS by RNA-sequencing, hoping to find out which circRNAs were involved in the stemness regulation of EBVaGC. we established a highly malignant EBVaGC cell line SNU-4th through long-term treatment of EBVaGC cell line SNU719 with 5-Fluorouraci in vivo passage, then we compared circRNAs expression between the fourth passage xenografts treated with 5-Fu and PBS by RNA-sequencing

2020-02-26 | GSE145894 | GEO

Mesothelioma xenografts in nude mice: PBS treated versus pirfenidone treated

Project description:Mesothelioma xenografts in nude mice: PBS treated versus pirfenidone treated

| PRJNA454010 | ENA

Genomic analysis of 5-FU treatment on colon cancer cells

Project description:This dataset contains RNAseq experiments of in vitro cultured MC38 colon cancer cell line treated with PBS or 5-FU

2021-01-01 | GSE160985 | GEO

Transcriptional profile of AML xenografts treated with either PBS or a combination of decitabine and cytarabine

Project description:The Affymetrix Human Genome U133 Plus 2.0 Array was used to examine the Genome wide transcriptional changes which follow the treatment of AML xenografts with either PBS control or combination of decitabine (DAC) and cytarabine (Ara-C). Animals were treated with PBS, DAC alone, Ara-C alone, DAC and Ara-C combined (D+A), DAC followed by Ara-C (D/A) or Ara-C followed by DAC (A/D).

2013-03-06 | GSE44857 | GEO

Transcriptional profile of AML xenografts treated with either PBS or a combination of decitabine and cytarabine

2013-03-06 | E-GEOD-44857 | biostudies-arrayexpress

A fourth Denisovan individual

Project description:A fourth Denisovan individual

| PRJEB20653 | ENA

FU methane

Project description:FU methane Metagenome

| PRJNA756936 | ENA

Mesothelioma xenografts in nude mice: PBS treated versus pirfenidone treated

Project description:Background: Malignant mesothelioma is an aggressive cancer with poor prognosis. It is characterized by prominent extracellular matrix, mesenchymal tumor cell phenotypes and chemoresistance. In this study, the ability of pirfenidone to alter mesothelioma cell proliferation and migration as well as mesothelioma tumor microenvironment was evaluated. Pirfenidone is an anti-fibrotic drug used in the treatment of idiopathic pulmonary fibrosis and has also anti-proliferative activities. Aims: Transcriptional profiling using RNA sequencing of human mesothelioma xenograft tumors treated with PBS or pirfenidone. Aim was to compare extracellular matrix and fibrosis related genes. Results: Treatment of mice harboring mesothelioma xenografts with pirfenidone alone did not reduce tumor proliferation in vivo. However, pirfenidone modified the tumor microenvironment by reducing the expression of extracellular matrix associated genes. In addition, GREM1 expression was downregulated by pirfenidone in vivo. Conclusion: By reducing two major upregulated pathways in mesothelioma and by targeting tumor cells and the microenvironment pirfenidone may present a novel anti-fibrotic and anti-cancer adjuvant therapy for mesothelioma.

2018-12-14 | GSE113803 | GEO

Differentially expressed miRNAs in xenografts and organoids derived from human cholangiocarcinoma [miRNA]

Project description:We established xenografts and organoids derived from human cholangiocarcinoma. To investigate the signature of cancer stem cells, miRNA expression profiles were analyzed in cholangiocarcinoma xenografts and organoids (passage 7). Microarray analyses were conducted in cholangiocarcioma xenografts and organoids (passage 7).

2016-04-01 | E-GEOD-67209 | biostudies-arrayexpress

Differentially expressed miRNAs in xenografts and organoids derived from human cholangiocarcinoma [miRNA]

2016-04-01 | GSE67209 | GEO